{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:59:50Z","timestamp":1770393590396,"version":"3.49.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Olaparib (OLA) is a poly ADP-ribose polymerase inhibitor (PARPi) indicated for solid cancers harboring\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutations. Recent evidences suggest that sensitivity to PARPis may also be influenced by other factors that impair the DNA repair mechanisms. Since various hematological malignancies exhibit these types of defects, this study aims to investigate further the mechanism of action of OLA in CLBL-1 and GL-1 canine cell lines, which showed different sensitivities to this PARPi.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CLBL-1 and GL-1 cell lines were exposed to OLA (12.5, 25, and 50 \u03bcM) for 24 and 48 h and were subjected to preliminary cell death evaluations by flow cytometry. Then, both immunoblotting for the assessment of Bcl-2 and Bcl-XL, and RNA-seq were carried out after 24 h of exposure to OLA 25 and 50 \u03bcM. As for whole-transcriptome analysis, reads were pseudo-aligned (Kallisto) to the reference transcriptome, and differential gene expression (DGE) and functional analyses were performed with edgeR and clusterProfiler R packages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The percentage of annexin V-positive cells after 24 h of incubation with OLA 50 \u03bcM was ~10%, increasing to ~40% in CLBL-1 cells and ~30% in GL-1 cells at 48 h. Bcl-2 and Bcl-XL expression increased after 24 h of incubation in CLBL-1 cells but decreased in GL-1 cells. DGE and functional analyses showed that, in CLBL-1 cells, the main processes affected by OLA were stress (e.g.,\n                      <jats:italic>ATF3, CEBPB<\/jats:italic>\n                      ) and apoptosis (e.g.,\n                      <jats:italic>BAX, BBC3<\/jats:italic>\n                      ). Conversely, in GL-1 cells, the regulation of tumor necrosis factor and interferon response-related terms, along with the upregulation of genes such as\n                      <jats:italic>IL6, TNF, IFIT3, GSDME<\/jats:italic>\n                      , and\n                      <jats:italic>IL18<\/jats:italic>\n                      , indicated the induction of pyroptosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The comprehensive transcriptomic analysis helped clarify the distinct mechanisms of OLA-induced cell death in CLBL-1 and GL-1 cells, which showed different sensitivities to OLA. Indeed, this PARPi appeared to interact with immune checkpoints, stress sensors, and interfere with cell proliferation, leading to various types of cell death. As canine lymphoma is a significant concern in veterinary oncology and a valuable model for its human counterpart, this study further confirms the potential of PARPi as a therapeutic approach in hematological malignancies in both species.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fvets.2026.1725824","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:22:00Z","timestamp":1770355320000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Insights into the olaparib-mediated cell death mechanisms in canine hematological malignancies: a different fate for CLBL-1 and GL-1 cell lines"],"prefix":"10.3389","volume":"13","author":[{"given":"Greta","family":"Mucignat","sequence":"first","affiliation":[{"name":"Department of Comparative Biomedicine and Food Science, University of Padua -Agripolis","place":["Legnaro, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Dejnaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Wroc\u0142aw University of Environmental and Life Sciences","place":["Wroc\u0142aw, Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Pauletto","sequence":"additional","affiliation":[{"name":"Department of Comparative Biomedicine and Food Science, University of Padua -Agripolis","place":["Legnaro, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Maria","family":"Lopparelli","sequence":"additional","affiliation":[{"name":"Department of Comparative Biomedicine and Food Science, University of Padua -Agripolis","place":["Legnaro, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mery","family":"Giantin","sequence":"additional","affiliation":[{"name":"Department of Comparative Biomedicine and Food Science, University of Padua -Agripolis","place":["Legnaro, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Pawlak","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Wroc\u0142aw University of Environmental and Life Sciences","place":["Wroc\u0142aw, Poland"]},{"name":"Department of Physiology and Pharmacology, University of Georgia","place":["Athens, GA, United States"]},{"name":"SMART Pharmacology, Precision One Health Initiative, University of Georgia","place":["Athens, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Dacasto","sequence":"additional","affiliation":[{"name":"Department of Comparative Biomedicine and Food Science, University of Padua -Agripolis","place":["Legnaro, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1292\/jvms.23-0204","article-title":"Second era of molecular-targeted cancer therapies in dogs","volume":"85","author":"Maeda","year":"2023","journal-title":"J Vet Med Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"116288","DOI":"10.1016\/j.biopha.2024.116288","article-title":"The power and the promise of synthetic lethality for clinical application in cancer treatment","volume":"172","author":"Liu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41420-025-02418-8","article-title":"Perspectives on cancer therapy\u2014synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges","volume":"11","author":"Peng","year":"2025","journal-title":"Cell Death Discov"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3390\/ijms26041768","article-title":"Exploring the therapeutic potential of BRCA1 and BRCA2 as targets in Canine Oncology: a comprehensive review of their role in cancer development and treatment","volume":"26","author":"Pasaol","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.21873\/anticanres.14286","article-title":"PARP inhibitors as therapeutic options for tyrosine kinase-dependent Leukemia: a review","volume":"40","author":"Machado","year":"2020","journal-title":"Anticancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.ajpath.2025.07.004","article-title":"Poly (ADP-Ribose) Polymerase 1 and 2 in B-Cell Lymphoma: pathogenic roles and therapeutic implications","volume":"195","author":"Molina-Alvarez","year":"2025","journal-title":"Am J Pathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","article-title":"Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies","volume":"15","author":"Padella","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.3390\/cancers13215328","article-title":"PARP inhibitors and haematological malignancies\u2014friend or foe?","volume":"13","author":"Skelding","year":"2021","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e16235","DOI":"10.15252\/emmm.202216235","article-title":"Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance","volume":"15","author":"Wang","year":"2023","journal-title":"EMBO Mol Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1111\/jvim.16893","article-title":"Novel genomic prognostic biomarkers for dogs with cancer","volume":"37","author":"Chon","year":"2023","journal-title":"J Vet Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3390\/cancers17040596","article-title":"What we know and do not yet know about the canine model of lymphoma in human medicine\u2014the current state of knowledge","volume":"17","author":"Bedkowska","year":"2025","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6279","DOI":"10.1038\/s41598-018-23207-7","article-title":"Comparative high-resolution transcriptome sequencing of lymphoma cell lines and de novo lymphomas reveals cell-line-specific pathway dysregulation","volume":"8","author":"Taher","year":"2018","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12917-016-0836-z","article-title":"Comprehensive genomic characterization of five canine lymphoid tumor cell lines","volume":"12","author":"Roode","year":"2016","journal-title":"BMC Vet Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1476-5829.2011.00299.x","article-title":"Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines","volume":"11","author":"Seiser","year":"2013","journal-title":"Vet Comp Onc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.leukres.2010.01.021","article-title":"Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma","volume":"34","author":"R\u00fctgen","year":"2010","journal-title":"Leuk Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1292\/jvms.58.469","article-title":"Establishment and characterization of a new canine B-cell leukemia cell line","volume":"58","author":"Nakaichi","year":"1996","journal-title":"J Vet Med Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s12917-025-04880-z","article-title":"PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer","volume":"21","author":"Pasaol","year":"2025","journal-title":"BMC Vet Res"},{"key":"B18","unstructured":"WS\n          \n          \n            \n              Andrews\n              S\n            \n            \n              Krueger\n              F\n            \n            \n              Seconds-Pichon\n              A\n            \n            \n              Biggins\n              F\n            \n          \n          FastQC. A quality control tool for high throughput sequence data. Babraham Bioinformatics\n          \n          2015"},{"key":"B19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat Methods"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","article-title":"Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences","volume":"4","author":"Soneson","year":"2015","journal-title":"F1000Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/nprot.2009.97","article-title":"Mapping identifiers for the integration of genomic datasets with the R\/Bioconductor package biomaRt","volume":"4","author":"Durinck","year":"2009","journal-title":"Nat Protoc"},{"key":"B24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/978-1-4939-3578-9_19","article-title":"It's DE-licious: a recipe for differential expression analyses of RNA-seq experiments using quasi-likelihood methods in edgeR","volume":"1418","author":"Lun","year":"2016","journal-title":"Methods Mol Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18129\/B9.bioc.EnhancedVolcano","author":"Blighe","year":"2023","journal-title":"Enhanced volcano: publication-ready volcano plots with enhanced colouring and labeling"},{"key":"B27","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","article-title":"et al. clusterProfiler 40: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"102090","DOI":"10.1016\/j.ctrv.2020.102090","article-title":"Targeting the DNA damage response for patients with lymphoma: preclinical and clinical evidences","volume":"90","author":"Carrassa","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e3225","DOI":"10.1002\/hon.3225","article-title":"Expression of \u201cDNA damage response\u201d pathway genes in diffuse large B-cell lymphoma: the potential for exploiting synthetic lethality","volume":"42","author":"Mansoor","year":"2024","journal-title":"Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/vco.13014","article-title":"Targeting ATR kinase as a strategy for canine lymphoma and leukaemia treatment","volume":"22","author":"Henklewska","year":"2024","journal-title":"Vet Comp Oncol"},{"key":"B31","first-page":"843","article-title":"The effect of common antineoplastic agents on induction of apoptosis in canine lymphoma and leukemia cell lines","volume":"28","author":"Pawlak","year":"2014"},{"key":"B32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.rvsc.2004.09.012","article-title":"Development of multidrug resistance in a canine lymphoma cell line","volume":"78","author":"Uozurmi","year":"2005","journal-title":"Res Vet Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/2159-8290.CD-12-0514","article-title":"Mechanisms of resistance to PARP inhibitors-three and counting","volume":"3","author":"Fojo","year":"2013","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jvim.12525","article-title":"P-Glycoprotein mediated drug interactions in animals and humans with cancer","volume":"29","author":"Mealey","year":"2015","journal-title":"J Vet Intern Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/jpet.121.000845","article-title":"Brain distribution of berzosertib: an ataxia telangiectasia and Rad3-related protein inhibitor for the treatment of glioblastoma","volume":"379","author":"Talele","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.tvjl.2013.10.022","article-title":"Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients","volume":"199","author":"Tomiyasu","year":"2014","journal-title":"Vet J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.canlet.2019.03.048","article-title":"Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD","volume":"454","author":"Dellomo","year":"2019","journal-title":"Cancer Lett"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2023.05.005","article-title":"Unifying targeted therapy for leukemia in the era of PARP inhibition","volume":"124","author":"Boila","year":"2023","journal-title":"Exp Hematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2407-11-38","article-title":"FLT3 mutations in canine acute lymphocytic leukemia","volume":"11","author":"Suter","year":"2011","journal-title":"BMC Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1038\/s41467-019-10460-1","article-title":"Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence","volume":"10","author":"Fleury","year":"2019","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41419-023-05963-1","article-title":"Bcl-2 family inhibitors sensitize human cancer models to therapy","volume":"14","author":"Valentini","year":"2023","journal-title":"Cell Death Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"14177","DOI":"10.1038\/s41598-024-64696-z","article-title":"Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts","volume":"14","author":"Nocquet","year":"2024","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3892\/ijo.2017.3914","article-title":"Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2\/Bcl-xL and PARP","volume":"50","author":"Yokoyama","year":"2017","journal-title":"Int J Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/10985549.2023.2229225","article-title":"Shared gene targets of the ATF4 and p53 transcriptional networks","volume":"43","author":"Baniulyte","year":"2023","journal-title":"Mol Cell Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neo.2021.01.004","article-title":"P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1\/2 and CDK9","volume":"23","author":"Tian","year":"2021","journal-title":"Neoplasia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41388-021-02141-5","article-title":"p53 partial loss-of-function mutations sensitize to chemotherapy","volume":"41","author":"Klimovich","year":"2022","journal-title":"Oncogene"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.3390\/cancers15194816","article-title":"TP53 mutation in acute myeloid leukemia: an old foe revisited","volume":"15","author":"Shin","year":"2023","journal-title":"Cancers"},{"key":"B48","doi-asserted-by":"publisher","first-page":"216797","DOI":"10.1016\/j.canlet.2024.216797","article-title":"Induction of IFIT1\/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis","volume":"588","author":"He","year":"2024","journal-title":"Cancer Lett"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e009032","DOI":"10.1136\/jitc-2024-009032","article-title":"PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD\/E axis in ovarian cancer","volume":"12","author":"Xia","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"RP89974","DOI":"10.7554\/eLife.89974.3","article-title":"The molecular mechanism and evolutionary divergence of caspase 3\/7-regulated gasdermin E activation","volume":"12","author":"Xu","year":"2023","journal-title":"Elife"},{"key":"B51","doi-asserted-by":"publisher","first-page":"592622","DOI":"10.3389\/fimmu.2020.592622","article-title":"Key Components of inflammasome and pyroptosis pathways are deficient in canines and felines, possibly affecting their response to SARS-CoV-2 Infection","volume":"11","author":"Cui","year":"2021","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41420-020-00349-0","article-title":"The caspase-3\/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer","volume":"6","author":"Jiang","year":"2020","journal-title":"Cell Death Discov"},{"key":"B53","doi-asserted-by":"publisher","first-page":"217961","DOI":"10.1016\/j.canlet.2025.217961","article-title":"BCL-2\/BCL-XL dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma","volume":"632","author":"Li","year":"2025","journal-title":"Cancer Lett"},{"key":"B54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbrc.2023.01.055","article-title":"PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage","volume":"646","author":"Kim","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1758835920944116","article-title":"PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers","volume":"12","author":"Lee","year":"2020","journal-title":"Ther Adv Med Oncol"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1725824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:22:03Z","timestamp":1770355323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1725824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":55,"alternative-id":["10.3389\/fvets.2026.1725824"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2026.1725824","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"article-number":"1725824"}}